This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Left side is Bid, Right side is Ask. Color grey is not of much signifigance. ASK is nice and thin right now
That L2 is tasty. I'm gonna spread it around on the general boards a bit
50,000 Shares hitting the ASK! 1 MM till .022's
VYCO looking good:
-solid accumulation over last several weeks
-longs buying and holding
-spread closing up
-board marks growing
-2nd Q ending soon, expect to see rev increase again
VYCO solid grass roots play. Why:
-200% rev increases
-$10BB industry
-Only FDA approved, patented cure for stroke related vision loss
-solid marketing plan
-already used in 3000 medical procedures, no smoke and mirrors here
~~VYCO~~200% rev increas, $10BB industry, Only FDA approved, patented cure for stroke related vision loss, already used in 3000 medical procedures, no smoke and mirrors here
VYCO accumulation, preparing for big move, nice spread
VYCO REV's up 200% last quarter. What will this Q hold?
VYCO: cures stroke related vision loss, only one FDA approved. Tight spread, ready to move soon
VYCO: strong GREEN finish yesterday, up 33%, grass roots accumulation, REV up 200%
~~VYCO~~ accumulating base of support. Tight spread ready to move soon, imho
The grass roots support here is gaining steam. The DD really inspires support from the old guard market gurus
VYCO .019 x .02, Grass roots play gaining steam, steady gainer with AMAZING dd
VYCO .019 x .02, Accumulation yesterday! Organic grass roots play gaining steam
VYCO .019 x .02, up 33% EOD, Accumulation!
VYCO .019 x .02, ready to move, up 33% EOD
VYCO Revenues up. Forecasts call for revenues of $2.9mm in 2012, $5.3mm in 2013
"Revenue up 198% Over First Quarter 2011; Vycor Medical Division Revenue up 222% Over 2011, NovaVision Division up 145%; Net Loss Reduced"
http://finance.yahoo.com/news/vycor-medical-inc-reports-first-130000889.html
Harbinger Research report: http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
SEC filings: http://ir.vycormedical.com/SEC
VYCO's NovaVision technology is the only FDA cleared treatment that restores vision lost by victims of stroke and traumatic brain injury.
Vycor NovaVision product offering is the first real, tested, proven treatment for a type of vision loss which the medical community has considered untreatable for over a hundred years. NovaVision literally restores sight to the blind. VYCO has generated a legitimate medical breakthrough.
"NovaVision provides a home-based treatment of vision rehabilitation after stroke or brain injury called Vision Restoration Therapy (VRTâ„¢). VRT is an FDA-cleared, patented, non-invasive medical device that enhances visual functions in patients with impairments due to stroke, surgical intervention, and traumatic brain injury (TBI). "
"70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car."
"Stroke and traumatic brain injury (TBI) victims are almost always told by their doctors that vision loss causedby neurological brain damage is permanent and irreversible; these doctors have been taught this "fact" since early in their careers, and they mostly accept it as a fact, without question. However, according to six Company-sponsored studies and fourteen independent studies, conducted over a period of 15 years, this is not a fact at all. It is instead a previously-valid medical conclusion based on old data and technology - it is not based on current research. We believe the new data regarding recently-developed technology (i.e. NovaVision's VRT and NeET) have clearly shown that vision loss can be at least partially restored in most cases..."
Read up on the science and research here, including 15 years of research and 20 clinical studies: www.novavision.com/clinical-studies
Big ballers buying up VYCO in the background consistently over the last weeks. Longs who have studied the DD know that this won't stay undiscovered for long.
Expecting to see some more ACCUMULATION!!!!!!!!!!!!!!
Good Morning, VYCOnians! ;-D What will today hold?
Great post! Got my eyes on AUMY
Up 33%, .019 x .02. .022 is just around the corner, imho
VYCO up 33.3% today. Closed at .019 x .02.
-strong patent suite
-no competition
-FDA approval: only FDA approved treatment for stroke related vision loss
-200% rev increase/ $10B market
-already used in 3000 medical procedures
yes I think we'll have a strong finish today. More longs joining the team.
~~VYCO~~ building a grassroots following. Up 33%. Accumulation play. Nice steady gainer
a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO up 33%, the DD is gathering a grass roots following of rabid fans. Check it out, way underated:
a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO staying GREEN! strong DD lacking in most penny's. Feast your eyes on this:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO essential DD lacking in most penny's. Feast your eyes on this:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
foresee.
Long and strong. Little foretastes like today paint the picture for where this is heading.
~~VYCO~~ setting up for a huge play, up 33%, steady accumulation, all grass roots interest. Read the DD and you'll see why:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf